证券代码：688189 证券简称：南新制药 公告编号：2023-064 湖南南新制药股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 湖南南新制药股份有限公司（以下简称"公司"或"南新制药"）拟使 用不超过人民币300,000,000.00元（含本数）闲置募集资金暂时补充流动资金， 并仅限用于公司的业务拓展、日常经营等与主营业务相关的生产经营活动。 公司本次使用部分闲置募集资金暂时补充流动资金的使用期限为自董事 会审议通过之日起不超过12个月，到期归还至募集资金专用账户。在此期间如遇 募集资金专用账户余额不能满足募集资金正常支付的情况，公司将根据实际需要 将已暂时补充流动资金的募集资金返回至募集资金专用账户。 公司于 2023 年 11 月 24 日召开第二届董事会第六次会议和第二届监事会第 五次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》， 同意公司使用不超过人民币 300,000,000.00 元（含本数）闲置募集资金暂时 ...

证券代码：688189 证券简称：南新制药 公告编号：2023-062 特此公告。 湖南南新制药股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南南新制药股份有限公司（以下简称"公司"）于 2022 年 12 月 29 日召开 第一届董事会第三十六次会议和第一届监事会第二十九次会议，审议通过了《关 于使用部分闲置募集资金暂时补充流动资金的议案》。为提高募集资金使用效率， 增加公司收益，减少公司财务费用，降低公司运营成本，维护公司和股东利益， 在确保募集资金投资计划正常进行的前提下，公司决定使用不超过人民币 300,000,000.00 元（含本数）闲置募集资金暂时补充流动资金，使用期限为自董 事会审议通过之日起不超过 12 个月，到期归还至募集资金专用账户。在此期间 如遇募集资金专用账户余额不能满足募集资金正常支付的情况，公司将根据实际 需要将已暂时补充流动资金的募集资金返回至募集资金专用账户。具体详情请见 公司于 2022 年 12 月 30 日在上海证券交易所网站（www.sse.com.cn）披 ...

证券代码：688189 证券简称：南新制药 公告编号：2023-061 湖南南新制药股份有限公司 关于公司诉讼结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重大内容提示 一、本次诉讼的基本情况 （一）公司诉 Synermore 缔约过失责任案 由于公司收购兴盟生物医药（苏州）有限公司（以下简称"兴盟生物"）股 权的事项已终止，公司认为 Synermore 存在缔约过失责任，应赔偿人民币 15,000 万元及公司因维权支付的合理费用。具体内容详见公司于 2023 年 2 月 2 日在上 海证券交易所网站（www.sse.com.cn）披露的《关于公司涉及诉讼的公告》（公 告编号：2023-007）。 （二）Synermore 诉公司缔约过失责任案 由于公司收购兴盟生物股权的事项已终止，Synermore 认为公司存在缔约过 案件所处的诉讼阶段：一审和解结案 公司所处的当事人地位：原告、被告 涉案的金额：（1）湖南南新制药股份有限公司（以下简称"公司"）诉 Synermore Company Limited（以下 ...

证券代码：688189 证券简称：南新制药 湖南南新制药股份有限公司 投资者关系活动记录表 编号：2023-001 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别 □现场参观 √其他 （ 2023 年湖南辖区上市公司 投资者网上集体接待日活动） 线上参加2023年湖南辖区上市公司投资者网上集体接待日活动的投 参与单位名称 及人员姓名 资者 时间 2023年11月2日 14:00-17:00 ...

证券代码：688189 证券简称：南新制药 公告编号：2023-059 湖南南新制药股份有限公司 关于法定代表人代行董事会秘书职责的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南南新制药股份有限公司（以下简称"公司"）于 2023 年 8 月 5 日在上 海证券交易所网站（www.sse.com.cn）披露了《关于常务副总经理、董事会秘书 辞职的公告》（公告编号：2023-053）。黄俊迪先生因个人原因申请辞去公司常务 副总经理、董事会秘书职务，在董事会秘书职务空缺期间，暂由公司副总经理、 财务总监李亮先生代为履行董事会秘书职责。 截至本公告披露日，李亮先生代行董事会秘书职责将满三个月。根据《上海 证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等有关规定，公司董事会秘书空缺超过三个月的，公司 法定代表人应当代行董事会秘书职责。因此，自 2023 年 11 月 5 日起，由公司法 定代表人、副董事长、总经理张世喜先生代行董事会秘书职责，直至公司完成董 事会秘书的 ...

证券代码：688189 证券简称：南新制药 公告编号：2023-060 湖南南新制药股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 11 月 24 日（星期五）至 11 月 30 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过湖南南新制药股份 有限公司（以下简称"公司"）邮箱 nanxin@nucien.com 进行提问。公司将在业 绩说明会上对投资者普遍关注的问题进行回答。 公司已于 2023 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）披 露了公司《2023 年第三季度报告》。为便于广大投资者更全面深入地了解公司 2023 年第三季度的经营成果和财务状况，公司计划于 2023 年 12 月 1 日（星期 五）14:00-15:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行 交流。 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将 ...

Financial Performance - The company's revenue for the third quarter was ¥48,309,175.65, a decrease of 67.15% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥27,757,679.02, with a year-to-date net profit of ¥650,517.07, reflecting a decline of 95.52%[5]. - The company reported a basic earnings per share of -¥0.1012 for the quarter, a decrease of 95.52% year-to-date[6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -¥28,665,688.55 for the quarter, with a year-to-date figure of ¥5,863,681.98, down by 31.12%[5]. - The net profit for the first three quarters of 2023 was CNY 998,459.62, a significant decline from CNY 3,723,876.14 in the previous year, reflecting challenges in profitability[20]. - The company reported a total profit of CNY -1,900,148.51 for the first three quarters of 2023, contrasting with a profit of CNY 6,083,796.26 in 2022, highlighting a significant downturn in financial performance[20]. Research and Development - Research and development (R&D) expenses totaled ¥17,045,021.46 for the quarter, representing an increase of 18.88%, and accounted for 35.28% of revenue, up by 25.53 percentage points[6]. - The company is currently conducting clinical trials for new projects, including hydrochloride mefloquine tablets and paracetamol inhalation solution, which has led to increased R&D investment[10]. - Research and development expenses increased to CNY 63,925,857.68 in 2023, up from CNY 38,936,841.28 in 2022, highlighting a focus on innovation[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,677,228,137.78, a decrease of 14.16% from the end of the previous year[6]. - Total current assets as of September 30, 2023, amount to ¥1,231,656,921.13, a decrease from ¥1,496,172,292.33 as of December 31, 2022[14]. - Total non-current assets as of September 30, 2023, are ¥445,571,216.65, down from ¥457,619,851.65 as of December 31, 2022[15]. - The company has a total asset of ¥1,677,228,137.78 as of September 30, 2023, compared to ¥1,953,792,143.98 as of December 31, 2022[15]. - The total liabilities decreased to CNY 379,858,009.80 in 2023 from CNY 657,420,475.62 in 2022, suggesting a reduction in financial leverage[19]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥88,584,510.48, indicating an increase compared to the previous year[5]. - Cash inflow from operating activities reached CNY 626,379,760.43 in the first three quarters of 2023, compared to CNY 406,204,343.61 in 2022, indicating improved cash generation[23]. - The net cash flow from operating activities was 88,584,510.48, compared to a negative cash flow of -149,920,202.51 in the previous period[24]. - Cash outflows from operating activities totaled 537,795,249.95, slightly down from 556,124,546.12[24]. - The ending balance of cash and cash equivalents was 501,891,678.69, down from 547,128,233.71[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,927[12]. - The largest shareholder, Hunan Pharmaceutical Development Investment Group Co., Ltd., holds 78,400,000 shares, accounting for 28.57% of total shares[12]. - Basic earnings per share for the first three quarters of 2023 were CNY 0.0024, down from CNY 0.0529 in the same period of 2022, indicating a decline in shareholder returns[21]. Operational Insights - The company experienced a significant decline in sales prices of major products, contributing to the drop in revenue and net profit[10]. - The company has not reported any audited financial statements for the third quarter[4]. - The company has not disclosed any significant new strategies or product developments during the reporting period[14]. - Total operating revenue for the first three quarters of 2023 was CNY 547,468,507.21, a decrease of 2.5% compared to CNY 562,058,852.86 in the same period of 2022[19]. - Total operating costs for the first three quarters of 2023 were CNY 508,120,982.75, slightly down from CNY 509,161,609.51 in 2022, indicating a stable cost management strategy[19].

证券代码：688189 证券简称：南新制药 公告编号：2023-058 湖南南新制药股份有限公司 关于参加 2023 年湖南辖区上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流工作，湖南南新制药股份有限公司（以下 简称“公司”）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有 限公司联合举办的“推动上市公司规范运作，保护中小投资者——2023 年湖南 辖区上市公司投资者网上集体接待日”活动。现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录“全景路演”网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2023年11 月2日（星期四） 14:00-17:00。届 时公司高级管理人员将在线就公司治理、发展战略、经营状况、融资计划和可持 续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参 与！ ...

西部证券股份有限公司 关于湖南南新制药股份有限公司 2023 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则（2020 年 12 月修订）》《上海证券交易所上市公司自律监管指引第 11 号 ——持续督导》等有关法律、法规的规定，西部证券股份有限公司（以下简称"保 荐人"）作为湖南南新制药股份有限公司（以下简称"南新制药"、"公司"） 持续督导工作的保荐人，负责南新制药上市后的持续督导工作，并出具本持续督 导跟踪报告。 序号 工作内容 持续督导情况 1 建立健全并有效执行持续督导工作制度，并针对 具体的持续督导工作制定相应的工作计划。 保荐人已建立健全并有效执行了持 续督导制度，并制定了相应的工作计 划。 2 根据中国证监会相关规定，在持续督导工作开始 前，与上市公司或相关当事人签署持续督导协议 明确双方在持续督导期间的权利义务，并报上海 证券交易所备案。 保荐人已与南新制药签订承销与保 荐协议，该协议明确了双方在持续督 导期间的权利和义务，并报上海证券 交易所备案。 3 通过日常沟通、定期回访、现场检查、尽职调查 等方式开展持续督导工作。 保荐人通过日常沟通 ...

Product Development and Market Competition - The core product, Palivizumab sodium injection, faces increased market competition due to the approval of 6 competitors' products during the reporting period [4]. - The company has initiated the development of new products, including Palivizumab inhalation solution and Palivizumab inhalation powder, to maintain its competitive edge in the antiviral drug market [4]. - The company has only obtained a patent for the synthesis method of Palivizumab trihydrate, leaving it vulnerable to generic competition [4]. - The company is actively developing a range of products in the influenza treatment sector, including the first domestic 1.1 class innovative drug for influenza, Palivizumab Sodium Injection [41]. - The company is conducting Phase I clinical trials for a modified new drug, Palivizumab Inhalation Solution, which aims to be the world's first nebulized inhalation antiviral drug for influenza [42]. - The company has a diverse product line for pain relief and fever reduction, including the unique compound ibuprofen tablets and the first pediatric ibuprofen suspension approved in China [42]. - The company is expanding its product offerings in chronic disease areas, with existing products like Benazepril Hydrochlorothiazide Tablets and Atorvastatin Calcium Tablets [42]. - The company has 22 new products in development, including 7 innovative drug projects and 13 generic drug projects [33]. Financial Performance - The company's revenue for the first half of 2023 reached 514 million yuan, an increase of 28.31% year-on-year [24]. - Sales revenue from antiviral drugs amounted to 463 million yuan, up 76.55% compared to the same period last year, driven by increased market demand due to flu outbreaks [24]. - The sales revenue from analgesics reached 4.2651 million yuan, showing a year-on-year growth of 109.38% [24]. - Basic earnings per share for the reporting period were 0.1035 yuan, representing a 59.49% increase from the previous year [25]. - The net profit attributable to shareholders reached CNY 28.41 million, a year-on-year increase of 59.49% driven by revenue growth [26]. - The operating revenue for the period was CNY 513.75 million, representing a 28.31% increase compared to the same period last year [32]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 34.53 million, up 182.21% year-on-year [26]. - The company achieved a total profit of 28.63 million yuan, reflecting an increase of 1,214.13 million yuan year-on-year [74]. Research and Development - The R&D investment as a percentage of operating income was 10.12%, up 2.40 percentage points from the previous year [25]. - The company achieved a 68.32% increase in R&D investment compared to the same period last year, totaling approximately ¥52 million, driven by clinical trials for new projects [50]. - The total R&D expenditure accounted for 10.12% of the company's revenue, an increase of 2.41 percentage points from the previous year [52]. - The company has developed a core technology platform for drug molecular design and discovery, enhancing the efficiency and cost-effectiveness of new drug development [43]. - The company has established a robust R&D model, focusing on independent research and development, with a team of core technical personnel having over ten years of experience in well-known institutions [36]. - The number of R&D personnel has increased to 80, representing 21.33% of the total workforce, up from 70 and 18.09% in the same period last year [57]. Legal and Regulatory Matters - The company is involved in a lawsuit against Synermore, seeking compensation of 150 million yuan for contractual liability, with the case still pending [5]. - The report indicates that the financial report has not been audited, raising potential concerns about the accuracy of the financial data presented [9]. - The company emphasizes the importance of monitoring ongoing litigation outcomes, which may affect future profits [7]. - The company received administrative regulatory measures from the China Securities Regulatory Commission, requiring corrections to previous accounting errors [143]. - The company submitted a rectification report to the Shanghai Stock Exchange on July 5, 2023, in response to regulatory warnings received on June 6, 2023 [144]. Environmental and Social Responsibility - The company reported an investment of 24.30 million yuan in environmental protection during the reporting period [103]. - The company has established environmental protection mechanisms and has not faced any administrative penalties from environmental protection authorities [104]. - The company has implemented measures to ensure compliance with pollution discharge standards, with all monitored pollutants reported within acceptable limits [105]. - The company has committed to reducing carbon emissions, focusing on energy conservation and green environmental practices, although direct CO2 emissions are not applicable [115]. Corporate Governance and Shareholder Matters - The company held three shareholder meetings during the reporting period, all resolutions were approved without any rejections [89]. - The first board of directors was restructured, with new non-independent directors elected: Chen Jianshe, Leng Ying, and Yuan Chaolong [93]. - The company’s board of directors and supervisory board underwent significant personnel changes, with multiple resignations and elections [91]. - The company has proposed a profit distribution plan and capital reserve conversion to increase share capital for the year 2022 [89]. - The company guarantees the independence and integrity of its assets, ensuring that all assets are under its control and not used to secure debts of other enterprises [119]. Market and Sales Strategy - The company is actively expanding its marketing network and has established a team for promoting products in the outpatient market [34]. - The marketing network covers nearly 30 provinces and cities, enhancing service to end customers and supporting stable sales growth [61]. - The company is planning to launch new products to create additional revenue and profit growth points [34]. - The company is focusing on expanding its product line in response to market demands and trends [24]. Financial Position and Cash Flow - The total assets at the end of the reporting period were CNY 1.87 billion, a decrease of 4.39% from the previous year [26]. - The company's cash and cash equivalents decreased by 12.85% to ¥621.80 million, down from ¥713.47 million at the end of the previous year [79]. - The total current assets as of June 30, 2023, amounted to ¥1,416,428,938.78, a decrease from ¥1,496,172,292.33 at the end of 2022, reflecting a decline of approximately 5.3% [183]. - The ending cash and cash equivalents balance was CNY 621,795,727.50, a decrease from CNY 597,350,491.97 at the end of the previous year [200]. - The company reported a significant increase in sales personnel activities due to the easing of COVID-19 restrictions, contributing to higher sales expenses, which rose by 20.97% to ¥309.75 million [76].